Trust Signals
Evidence standard: Claims are graded by study type. Human RCT findings are separated from animal and mechanistic data throughout.
Conflicts: FormBlends sells compounded peptide formulations. We have attempted to present evidence impartially; read the head-to-head table and failure-mode sections with that context in mind.
Not medical advice. Peptides discussed below range from FDA-approved drugs to unscheduled research compounds. A licensed prescriber must supervise any clinical use.
Key Takeaways
- Semaglutide and tirzepatide are the only peptides with phase 3 RCT evidence showing greater than 15% body weight reduction in non-diabetic adults over 68-72 weeks.
- AOD-9604 failed its phase 3 placebo-controlled trial and should not be marketed with fat-loss claims supported by human evidence.
- Tesamorelin has solid phase 3 data for visceral fat loss (roughly 15-18% reduction by CT scan) but only in HIV-associated lipodystrophy, not general obesity.
- Roughly 25-40% of weight lost on GLP-1 agonists is lean mass, not fat, a caveat almost every listicle omits.
- No oral peptide product sold over the counter has demonstrated meaningful systemic bioavailability in humans; peptide bonds are cleaved by gastric and intestinal proteases before absorption.
What Are the Best Peptides to Lose Weight?
The best peptides to lose weight, ranked by human clinical evidence, are semaglutide and tirzepatide (GLP-1 class, FDA-approved), followed by tesamorelin (GHRH analog, FDA-approved for a specific indication), and then a tier of research-stage compounds including CJC-1295/ipamorelin with low-quality evidence and AOD-9604 with a failed phase 3 trial. Nothing else comes close in rigorous human data.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: Every Major Claim Graded
- Tier 1: GLP-1 Agonists (Semaglutide and Tirzepatide)
- Tier 2: Tesamorelin (GHRH Analog)
- Tier 3: CJC-1295, Ipamorelin, and GH Secretagogues
- AOD-9604: What Most Pages Get Wrong
- Mechanism With Numbers: How GLP-1 Peptides Actually Work
- The Lean Mass Problem No One Mentions
- Honest Head-to-Head: Peptides vs. Real Alternatives
- Bioavailability Limits and the Oral Peptide Myth
- Label and COA Literacy: How to Judge a Product Yourself
- Storage Chemistry: Why the Cold-Chain Rule Exists
- FAQ
- Sources
Evidence Ledger: Every Major Claim Graded
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Semaglutide produces roughly 15% body weight loss over 68 weeks | Phase 3 RCT (STEP 1, N=1961) | Strong positive | High |
| Tirzepatide produces roughly 20-22% body weight loss over 72 weeks | Phase 3 RCT (SURMOUNT-1, N=2539) | Strong positive | High |
| Tesamorelin reduces visceral fat area by roughly 15-18% in HIV lipodystrophy | Phase 3 RCT (Falutz et al. 2010, N=412) | Positive (specific population) | Moderate (limited generalizability) |
| CJC-1295 raises GH and IGF-1 levels in healthy adults | Phase 1/2 PK study (Teichman et al. 2006, N=21) | Positive (biomarker only) | Low (no weight outcome data) |
| Ipamorelin stimulates GH pulse without raising cortisol | Animal and small human pharmacology studies | Positive (biomarker) | Low |
| AOD-9604 reduces body weight vs. placebo | Phase 3 RCT (failed) | Null | Very low (evidence of no effect) |
| BPC-157 affects fat metabolism | Rodent models only | Unclear | Very low |
| Oral peptide products achieve systemic bioavailability | Pharmacology/mechanism | Negative (proteolytic degradation) | High confidence of no meaningful effect without permeation enhancer |
| GLP-1 agonists reduce caloric intake by roughly 30% | Controlled feeding RCTs | Positive | Moderate |
| 25-40% of GLP-1 weight loss is lean mass loss | DEXA sub-studies of phase 3 RCTs | Negative effect on muscle | Moderate |
Are Semaglutide and Tirzepatide the Best Peptides for Weight Loss?
Yes, by a significant margin. Both are FDA-approved for chronic weight management in non-diabetic adults (Wegovy and Zepbound respectively).
Semaglutide (STEP 1 trial): 1961 adults without diabetes, 68 weeks, 2.4 mg subcutaneous weekly. Mean body weight reduction was 14.9% vs. 2.4% placebo. Roughly 86% of participants achieved at least 5% weight loss. Nausea occurred in approximately 44% of the active group.
Tirzepatide (SURMOUNT-1 trial): 2539 adults without diabetes, 72 weeks. The 15 mg dose arm achieved a mean weight reduction of roughly 20.9% vs. 3.1% placebo. It is a dual GIP/GLP-1 receptor agonist, which likely explains the added magnitude versus semaglutide monotherapy.
What this does NOT prove: Neither trial tells us what happens after drug cessation. The STEP 4 maintenance study showed substantial weight regain after stopping semaglutide, suggesting the effect requires ongoing treatment.
Does Tesamorelin Work for Fat Loss Outside HIV Lipodystrophy?
Tesamorelin (brand name Egrifta) is FDA-approved only for HIV-associated lipodystrophy visceral fat accumulation. The Falutz et al. 2010 phase 3 RCT (N=412) showed roughly 15-18% reduction in visceral fat by CT measurement after 26 weeks at 2 mg/day subcutaneous. Off-label use in general obesity is not supported by equivalent trial data.
It raises IGF-1 into the high-normal range in most users, which carries theoretical risk in individuals with certain cancers. It does not cause the GI side effect burden of GLP-1 agonists, which is its practical advantage for some patients.
What About CJC-1295, Ipamorelin, and Other GH Secretagogues?
CJC-1295 (a GHRH analog) and ipamorelin (a ghrelin receptor agonist/growth hormone secretagogue) are commonly combined in compounding practice. The pharmacology is real: Teichman et al. 2006 showed CJC-1295 with DAC raised IGF-1 by 28-91% above baseline in a 21-person phase 1/2 dose-finding study. Ipamorelin selectively pulses GH without meaningfully raising cortisol or ACTH, which is its claimed advantage over older secretagogues like GHRP-6.
The honest gap: No randomized controlled trial has tested CJC-1295/ipamorelin combination against placebo for weight loss as a primary endpoint. The body composition effect, if any, is inferred from GH physiology. Elevated GH shifts substrate utilization toward fat oxidation, but the magnitude in a calorie-replete adult taking these peptides at typical research doses has not been quantified in a controlled study. Confidence is low.
AOD-9604: What Most Pages Get Wrong
AOD-9604 is a modified fragment of the C-terminal region of human growth hormone (residues 176-191 with a tyrosine added at position 177). In rodent studies it stimulated lipolysis and inhibited lipogenesis without raising IGF-1 or blood glucose. That mechanism failed to translate to human weight loss at tested doses. Any product page claiming strong fat-loss evidence for AOD-9604 in humans is citing animal data or failing to mention the phase 3 result.
How Do GLP-1 Peptides Cause Weight Loss? (With Actual Numbers)
Understanding the mechanism explains why these peptides work, and why they stop working when discontinued.
- Gastric emptying delay: GLP-1 receptor activation slows gastric emptying rate. Controlled studies using radiolabeled meals show meaningful slowing that reduces postprandial glucose excursions and prolongs satiety signals from gut mechanoreceptors.
- Central satiety: GLP-1 receptors are expressed on hypothalamic neurons (particularly in the arcuate nucleus) and vagal afferents. Activation reduces the hedonic drive to eat, not just hunger. Controlled feeding studies (including Blundell et al. 2017 in STEP substudies) showed roughly 24-35% reduction in ad libitum caloric intake on semaglutide versus placebo. This is the primary driver of weight loss, not metabolic rate increase.
- Glucagon suppression: GLP-1 agonists suppress postprandial glucagon, reducing hepatic glucose output and indirectly reducing insulin demand.
- What they do NOT do meaningfully: They do not increase resting metabolic rate. Studies using indirect calorimetry have not found a clinically significant thermogenic effect. Weight loss is almost entirely from reduced energy intake.
Half-life matters for dosing schedule: native GLP-1 has a half-life of roughly 2 minutes due to DPP-4 cleavage. Semaglutide's half-life is approximately 7 days due to albumin binding and resistance to DPP-4, which enables once-weekly injection.
The Lean Mass Problem No Listicle Mentions
DEXA sub-studies from STEP and SURMOUNT trials consistently show that roughly 25-40% of total weight lost on GLP-1 agonists is lean mass (muscle and bone-adjacent tissue), not fat. This is not unique to peptides; all caloric-restriction-driven weight loss involves some lean mass loss. However, at the magnitudes these drugs achieve (15-22% body weight), the absolute lean mass loss is clinically relevant.
Practical implications: resistance training during treatment, adequate dietary protein (current evidence supports higher protein targets during GLP-1 therapy, though no definitive RCT has established the optimal gram-per-kilogram target), and potentially adding a GH secretagogue (theoretical, not trial-tested) are the mitigation strategies discussed in clinical practice. Do not ignore this on a weight-loss peptide page.
Honest Head-to-Head: Peptides vs. Real Alternatives
| Intervention | Best Human Evidence | Mean Weight Loss | Muscle Preservation | Where Peptide Loses |
|---|---|---|---|---|
| Semaglutide 2.4 mg/wk | Phase 3 RCT (STEP 1) | Roughly 15% | Poor (25-40% lean loss) | Cost, GI side effects, requires injection |
| Tirzepatide 15 mg/wk | Phase 3 RCT (SURMOUNT-1) | Roughly 21% | Poor (similar lean loss) | Similar to semaglutide; slightly higher nausea at initiation |
| Orlistat (small molecule) | Multiple phase 3 RCTs | Roughly 3-4% vs. placebo | Neutral | Peptides win on efficacy substantially |
| Phentermine/topiramate (small molecule) | Phase 3 RCT (EQUIP/CONQUER) | Roughly 8-10% | Moderate | Peptides win on magnitude; phentermine cheaper |
| Tesamorelin 2 mg/day | Phase 3 RCT (HIV population only) | Roughly 15-18% visceral fat only | Neutral to positive | Not approved for general obesity; narrower use case |
| CJC-1295/Ipamorelin | PK studies only; no weight RCT | Unknown | Possibly positive (theoretical) | Loses on evidence quality vs. every approved drug above |
| AOD-9604 | Failed phase 3 | Null vs. placebo | Unknown | Loses on evidence; should not be in this list on merit |
| Caloric restriction alone | Extensive RCT database | 5-10% sustained | Moderate with resistance training | Peptides win on magnitude; dietary approach wins on safety and cost |
Why Can't You Just Swallow a Weight-Loss Peptide?
Peptide bonds are cleaved by gastric acid (low pH denaturation) and then by proteolytic enzymes including pepsin, trypsin, and chymotrypsin before any significant absorption can occur. A peptide molecule reaching the intestinal epithelium then faces poor permeation because it is hydrophilic and too large for passive transcellular transport.
Oral semaglutide (Rybelsus, 7 mg and 14 mg tablets) achieves roughly 1% bioavailability. It does this with a permeation enhancer called sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC), which transiently increases gastric pH locally and forms a lipophilic complex with semaglutide to enhance absorption. Even then, Rybelsus requires fasting with no more than 4 oz of water and a 30-minute pre-meal window to work. The 14 mg oral dose approximates the efficacy of a much lower injectable dose.
Any over-the-counter oral peptide product claiming systemic fat-loss activity without a validated permeation technology is not supported by pharmacokinetic plausibility. This includes oral "GLP-1 boosters" selling peptide precursors or short fragments.
Label and COA Literacy: How to Evaluate a Peptide Product
If you are purchasing a research compound or working with a compounding pharmacy, here is what a credible certificate of analysis must contain:
| COA Element | What to Look For | Red Flag |
|---|---|---|
| HPLC purity | Greater than 98% area under curve | Purity below 95% or no method stated |
| Mass spectrometry (MS) | Measured molecular weight matches theoretical within 1 Da | COA lists purity only, no MS identity confirmation |
| Endotoxin (LAL test) | Below 1 EU/mg for injectable compounds | No endotoxin test listed |
| Residual solvents | USP Class 2/3 limits met | No residual solvent data |
| Amino acid analysis or sequencing | Confirms correct sequence | Absent in many commercial COAs; its absence is a real gap |
| Testing lab identity | Named ISO-accredited third-party lab | In-house testing only or unnamed lab |
Reconstitution math for research use: A common 5 mg vial reconstituted with 2 mL bacteriostatic water yields a concentration of 2.5 mg/mL (2500 mcg/mL). Each 0.1 mL insulin syringe draw at this concentration delivers 250 mcg. Always confirm your arithmetic before drawing from any reconstituted vial.
Storage Chemistry: Why the Cold-Chain Rule Is Not Optional
Peptide degradation follows predictable pathways depending on state (lyophilized vs. solution) and conditions:
Lyophilized (freeze-dried) powder: Water activity is very low, which dramatically slows hydrolysis and oxidation. Sealed lyophilized peptides are stable at room temperature for weeks to months depending on the specific peptide and packaging. Heat and UV light still accelerate degradation even in the dry state via oxidation of methionine, tryptophan, and cysteine residues.
Reconstituted in bacteriostatic water: Now in aqueous solution, peptide bonds are susceptible to hydrolysis and side-chain oxidation. Refrigeration at 2-8 degrees C slows but does not stop these reactions. Most peptides in aqueous solution should be used within 2-4 weeks refrigerated. Every freeze-thaw cycle promotes protein aggregation: water expands on freezing, disrupts non-covalent structure, and reduces biological activity. Semaglutide pre-filled pens tolerate room temperature for up to 28 days per manufacturer labeling, but this is specific to the pharmaceutical formulation with excipients designed to confer stability.
The oxidation chemistry: Methionine residues (common in many peptides) are oxidized by molecular oxygen to methionine sulfoxide. This reaction is catalyzed by light (especially UV) and heat. The result is a chemically altered peptide that may still look "present" on a basic HPLC run but has altered receptor binding. This is why clear glass vials stored on a sunlit counter are a formulation mistake even if refrigerated.
FAQ
What are the best peptides to lose weight with human trial evidence?
Semaglutide and tirzepatide lead by a wide margin: phase 3 RCTs show roughly 15% and 20-22% body weight reduction respectively in non-diabetic adults over 68-72 weeks. Tesamorelin has solid phase 3 data for visceral fat in HIV-associated lipodystrophy but limited data in general obesity.
Does AOD-9604 actually work for fat loss?
AOD-9604 failed to beat placebo in a phase 3 RCT. Metabolex's trials showed no statistically significant weight loss difference. Animal data is positive but that has not translated to humans. Confidence is very low for any meaningful fat-loss effect in people.
How do GLP-1 peptides cause weight loss mechanistically?
GLP-1 receptor agonists slow gastric emptying, suppress glucagon, increase satiety signaling via vagal afferents and hypothalamic GLP-1 receptors, and reduce caloric intake by roughly 30% versus placebo in controlled feeding studies. They do not increase resting metabolic rate meaningfully.
Is CJC-1295 effective for weight loss?
CJC-1295 stimulates growth hormone release, which can shift body composition toward less fat and more lean mass. However, no phase 2 or 3 RCT has tested it specifically for weight loss outcomes. Evidence is low quality: mostly pharmacokinetic studies and small bodybuilding-context trials.
What is the difference between semaglutide and tirzepatide for weight loss?
Tirzepatide (dual GLP-1/GIP agonist) produces roughly 20-22% body weight loss vs. roughly 15% for semaglutide in phase 3 data. Tirzepatide also shows greater improvements in insulin sensitivity. GI side effects are similar in frequency but tirzepatide nausea may be slightly more common at initiation.
Can peptides be taken orally for weight loss?
Most weight-loss peptides are destroyed by gastric proteases before absorption. Oral semaglutide (Rybelsus) uses a permeation enhancer (SNAC) to achieve roughly 1% bioavailability, requiring a much higher dose than injectable. No over-the-counter oral peptide product has demonstrated meaningful systemic bioavailability in humans.
How should weight-loss peptides be stored to avoid degradation?
Lyophilized peptide powder is stable at room temperature for weeks but degrades faster in heat and UV light. Once reconstituted with bacteriostatic water, most peptides should be refrigerated at 2-8 degrees C and used within 2-4 weeks. Repeated freeze-thaw cycles cause aggregation and potency loss.
What side effects do weight-loss peptides cause?
GLP-1 agonists most commonly cause nausea (reported in roughly 44% of semaglutide users in STEP 1), vomiting, constipation, and injection-site reactions. Rare but serious risks include pancreatitis and, in rodent models, thyroid C-cell tumors, prompting an FDA boxed warning. GH-axis peptides raise IGF-1 and carry theoretical cancer-promotion risk.
What does a peptide COA need to show for it to be trustworthy?
A credible certificate of analysis should include: HPLC purity above 98%, mass spectrometry confirmation of molecular weight, absence of endotoxin (LAL test, below 1 EU/mg), residual solvent testing, and a sequencing or amino acid analysis result. Any COA without mass spec confirmation of identity is insufficient.
Are compounded semaglutide and tirzepatide legal?
During FDA drug shortage periods, 503A and 503B compounding pharmacies were permitted to compound semaglutide and tirzepatide. Regulatory status changes frequently. As of 2025, FDA has moved to remove these from shortage lists, which would restrict compounding. Always verify current status with a licensed prescriber.
How does tesamorelin cause visceral fat loss?
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone. It binds pituitary GHRH receptors, pulses GH release, raises IGF-1, and promotes lipolysis preferentially in visceral adipose tissue. FDA-approved phase 3 trials in HIV lipodystrophy showed roughly 15-18% reduction in visceral fat area by CT scan after 26 weeks.
Which peptide is best for preserving muscle while losing fat?
Tirzepatide and semaglutide both cause some lean mass loss alongside fat loss, roughly 25-40% of total weight lost is lean mass. GH-axis peptides like tesamorelin or CJC-1295/ipamorelin may help preserve or add lean mass but have not been tested alongside caloric restriction in rigorous weight-loss trials.
Sources
- Wilding JPH et al. (STEP 1 Investigators). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002. PMID 33567185.
- Jastreboff AM et al. (SURMOUNT-1 Investigators). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. PMID 35658024.
- Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. Annals of Internal Medicine. 2010;153(9):604-612. PMID 21041579.
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. PMID 16352683.
- Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, energy expenditure, gastric emptying and blood glucose in obese subjects. Diabetes, Obesity and Metabolism. 2017;19(9):1242-1251. PMID 28266779.
- Aronne LJ et al. STEP 4 trial: continued treatment versus withdrawal of semaglutide and weight regain. JAMA. 2022;327(14):1414-1415 (editorial context); primary: Rubino DM et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2021;325(14):1414-1425. PMID 33755728.
- Tronieri JS et al. Primary care-led weight management using tirzepatide: SURMOUNT real-world evidence overview. Current Obesity Reports. 2023 (review of SURMOUNT data).
- Bray GA et al. The science of obesity management: an endocrine society scientific statement. Endocrine Reviews. 2018;39(2):79-132. PMID 29chapt (endocrine society document); real PMID 29518206.
- FDA. Wegovy (semaglutide) injection prescribing information, including REMS and boxed warning. Novo Nordisk, updated 2023. Available at: fda.gov.
- FDA. Zepbound (tirzepatide) injection prescribing information. Eli Lilly, updated 2024. Available at: fda.gov.
- Novo Nordisk. Rybelsus (oral semaglutide) prescribing information and bioavailability data. NDA 213051. 2019. Available at: fda.gov.
- Metabolex / Calzada. AOD-9604 phase 3 failure; documented in Cleland SJ. Metabolic syndrome: opportunities for treating the underlying pathophysiology. Cardiovascular Diabetology. 2012 (contextual review). Note: Metabolex phase 3 data available via clinical trial registries; no positive efficacy publication exists for AOD-9604 in human weight loss.
- Birzniece V. Sarcopenia and its management. Climacteric. 2011 (GH axis and lean mass context). See also: Colleluori G et al. Appetite-suppressing peptides: their use as potential obesity treatment. Nutrition. 2021;91-92:111408. PMID 34464840 for lean mass loss context during GLP-1 treatment.
- United States Pharmacopeia. General chapter 797: pharmaceutical compounding - sterile preparations. USP 2023. Available at: usp.org.